In the last week of September 2023 we dosed patient number 31 and 32 with the highest dose of MBS8 ever dosed to any human being.
This was also to our knowledge the highest dose of a TL7 agonist ever administered to any patient to our knowledge. This is only possible due to the lipid formulation used for MBS8, which compared to benchmark compounds has shown an approximately 5-10 fold increase in therapeutic index. Not only show MBS8 better tolerability than benchmark compounds, it also has a much more potent antitumor activity in preclinical models, which we have high hopes will translate into benefits for patients with increased life span, tumor reductions and even complete cures.
